finanzen.net

Aclaris Therapeutics - 9 Asse im Ärmel!

Seite 1 von 5
neuester Beitrag: 22.07.20 17:49
eröffnet am: 03.05.19 12:25 von: moneywork4. Anzahl Beiträge: 123
neuester Beitrag: 22.07.20 17:49 von: Balu4u Leser gesamt: 13944
davon Heute: 9
bewertet mit 1 Stern

Seite: 1 | 2 | 3 | 4 | 5 | 5   

03.05.19 12:25
1

497 Postings, 463 Tage moneywork4meAclaris Therapeutics - 9 Asse im Ärmel!

Interessanter Biotech-Wert mit einer prallen Pipeline

https://www.aclaristx.com/pipeline/

https://www.aclaristx.com/

Kursziele bis 50 USD (Kurs aktuell: 6,06 USD)

April 26, 2019   Healthcare, Top Market News   0 Comments
Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)
By Carrie Williams

[Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)] In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS ? Research Report), with a price target of $50. The company?s shares closed yesterday at $6.83, close to its 52-week low of $5.04.

Chen commented:

   ?We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of 50 USD.

https://www.analystratings.com/articles/...ris-therapeutics-inc-acrs/  
Seite: 1 | 2 | 3 | 4 | 5 | 5   
97 Postings ausgeblendet.

10.01.20 16:22

5797 Postings, 1152 Tage VassagoACRS 2,08$ (+12%)

11.01.20 11:19

3883 Postings, 786 Tage PhönixxIch hoffe..

..die 1,xx $ sehen wir nie wieder!!  

29.01.20 19:00

19142 Postings, 3775 Tage Balu4uEcht traurig hier,

22.02.20 14:33

19142 Postings, 3775 Tage Balu4u1,45USD +0,11USD +8,21%

Wäre mal an der Zeit, dass es hier mal aufwärts geht.  

26.02.20 11:57
1

5797 Postings, 1152 Tage VassagoACRS 1.37$

Zahlen für 2019

  • Umsatz 4 Mio. $
  • Verlust 161 Mio. $
  • Cash 75 Mio. $
  • MK 57 Mio. $

   "Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2019, will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential business development transactions or financing activities."

http://investor.aclaristx.com/news-releases/...ter-and-full-year-2019

 

26.02.20 12:13

276 Postings, 3050 Tage mirko75oje

ordentlicher Verlust, hmm  

26.02.20 14:50

145 Postings, 3504 Tage m4machoNasdaq Premarket +14% ;-)

26.02.20 14:51

145 Postings, 3504 Tage m4machoNadaq Pre Market + 14%

10.03.20 11:44

5797 Postings, 1152 Tage VassagoACRS 0.99$ (-11%)

MK 41 Mio. $  

09.06.20 22:55

19142 Postings, 3775 Tage Balu4uEndlich mal wieder über 1,50

17.06.20 14:02
1

5797 Postings, 1152 Tage VassagoACRS 2.78$ (vorbörslich +88%)

ATI-450 darf bei COVID-19 Patienten getestet werden

https://investor.aclaristx.com/news-releases/...or-initiated-clinical

Zahlen für Q1/20

  • Umsatz 1,4 Mio. $
  • Verlust 15,6 Mio. $
  • Cash 79 Mio. $
  • MK 62 Mio. $ (auf Basis des Schlusskurses von gestern bei 1.48$)

https://investor.aclaristx.com/news-releases/...uarter-2020-financial


 

17.06.20 15:58

5803 Postings, 4125 Tage Kleine_prinzsuper news..

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

https://finance.yahoo.com/news/...vestigator-initiated-110110352.html

 

17.06.20 16:15

5803 Postings, 4125 Tage Kleine_prinzBald müssen auch darüber news kommen..

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

https://www.globenewswire.com/news-release/2019/...-of-Common-Wa.html

 

17.06.20 16:27

5803 Postings, 4125 Tage Kleine_prinzInfos zu Aclaris ATI-450

Aclaris Says FDA Clears IND To Evaluate ATI-450 MK2 Inhibitor - Quick Facts

Jun. 17, 2020, 01:35 PM

(RTTNews) - Clinical-stage biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) announced Wednesday that the U.S. Food and Drug Administration (FDA) has allowed an investigational new drug (IND) application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19.

Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome (CRS) in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial.


https://markets.businessinsider.com/news/stocks/...k-facts-1029316791

Info zu.. Aclaris Pipeline ATI-450

https://www.aclaristx.com/pipeline/

 

17.06.20 16:53

5803 Postings, 4125 Tage Kleine_prinzBald platz der deckel Pre-Market High..$4.99

Pre-Market Volume    1,713,269
Pre-Market High    $4.99 (07:30:52)
Pre-Market Low    $2.13 (08:55:52)

https://www.nasdaq.com/market-activity/stocks/acrs/pre-market


 

17.06.20 17:25

558 Postings, 1883 Tage oli25Schöne News

nur leider nicht mehr viel übrig vom dicken Plus.
Schade.
Aber vlt. gehts ja jetzt nachhaltig nach oben.
Ich drücke die Daumen.
Potential ist jedenfalls da und noch einiges in der Pipeline.  

17.06.20 17:29

19142 Postings, 3775 Tage Balu4uJa, endlich mal wieder ein Lebenszeichen

aber wie bereits erwähnt alles verpufft. Aber da sieht man auch was für Potentia dahinter steckt bzw. wie schnell es mal gehen kann. Jetzt muss man aufpassen, dass sie nicht ins Minus läuft

https://old.nasdaq.com/de/symbol/acrs/real-time  

19.06.20 20:53
1

19142 Postings, 3775 Tage Balu4uDie ganzen Gewinne wieder dahin...

vielleicht sollte ich mal ne Verkaufsorder mit 4 Euro einstellen, dann kann mir das mit permarket Explosion bei den Amis nicht mehr passieren. Ansonsten kannst hier keine Gewinne realisieren, wenn man nicht den ganzen Tag am Computer ist...  

08.07.20 00:10

5803 Postings, 4125 Tage Kleine_prinzGute News Aclaris Therapeutics

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). ATI-1777 is another compound generated from the Aclaris KINect™ drug discovery platform, and was specifically developed as a topical “soft” drug.

https://finance.yahoo.com/news/aclaris-therapeutics-submits-investigational-drug-200110803.html

 

10.07.20 21:31

5803 Postings, 4125 Tage Kleine_prinzBald müsste es news darüber geben..

If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

 

17.07.20 11:21

5803 Postings, 4125 Tage Kleine_prinzInteressant..

New Drug for COVID-19 Treatment is Developed in St. Louis with Clinical Trial in Kansas

--------------------------------------------------

Aclaris is supporting an investigator-initiated trial of ATI-450 in 36 hospitalized patients with COVID-19, and will provide funding and the clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial located in Kansas City, Kansas.

The clinical trial is underway to treat patients with the novel coronavirus because COVID-19 can cause acute respiratory distress syndrome, ARDS.

“Literature that’s come out over the last four or five months suggests one of the causes of ARDS is a hyperactive immune response, so the immune system is triggered when you get the viral infection, but for some reason the immune system goes a little haywire and this results in an inflammatory state,” explained Monahan. “The data suggests that this inflammatory state, this hyperinflammation, is associated with an upregulation of certain proteins that come from both diseased tissue and immune cells, called cytokines. And these cytokines could be the culprit in driving this ARDS and the inflammation seen in the lung in COVID-19 patients.”

Monahan explained the reason it’s believed ATI-450 will work as a rheumatoid arthritis treatment is because the drug downregulates cytokines, inhibiting their production.

https://www.hecmedia.org/posts/...uis-with-clinical-trial-in-kansas-3

 

21.07.20 08:44

19142 Postings, 3775 Tage Balu4u2,45USD +0,24USD +10,86%

Neues Jahreshoch





 

22.07.20 17:49

19142 Postings, 3775 Tage Balu4uImmer wieder Ausbruchsversuche...

Seite: 1 | 2 | 3 | 4 | 5 | 5   
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Apple Inc.865985
Daimler AG710000
Deutsche Bank AG514000
BioNTech SE (spons. ADRs)A2PSR2
Wirecard AG747206
Amazon906866
TeslaA1CX3T
Deutsche Telekom AG555750
BayerBAY001
Plug Power Inc.A1JA81
Ballard Power Inc.A0RENB
AlibabaA117ME
NEL ASAA0B733
BASFBASF11
Microsoft Corp.870747